Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development

Life Sciences, Drug Discovery & Development, Preclinical,
  • Monday, April 19, 2021

There are many considerations for Immunology and Immunotoxicology (I&I) assessments that are needed during the early phase of drug development. The talk will outline when to consider different I&I assay services and the regulatory and scientific considerations for these that will influence the appropriate biological interpretation of the immune response.

Register for this webinar to hear a talk given by James Munday and Chris Cooper, where they will give an outline of how to perform the appropriate safety assessments to show that there is no adverse immunotoxicology associated with the development of new therapeutic entities.


James Munday, Covance by Labcorp

James Munday, PhD, EU Lead, Immunology & Immunotoxicology, Covance by Labcorp

James Munday completed his doctorate at the University of Oxford in the field of Molecular and Cellular immunology. The work he carried out during this time lead to several publications on a family of cell adhesion molecules known as Siglecs (Sialic acid binding immunoglobulin like lectins). After completion of his doctorate, he continued his academic career as a postdoctoral scientist at the Mount Sinai School of Medicine in New York. This work focused on early haematopoiesis and vasculogenesis in embryonic stem cells.

After successful completion of this position, he gained his first position in the pharmaceutical Industry as a Senior Scientist at Celltech/UCB in the Assay Technologies group. This role supported the development and implementation of assays that assess biomarkers for PK/PD relationships to predict potency and efficacy of compounds in-vivo for a variety of immunology based disease endpoints.

He then moved to Quotient Bioresearch, where he worked on a diverse range of bioanalytical based projects and biomedical testing for external pharmaceutical clients. This led to his first role at Covance as a Study Director in the Immunochemistry Department. After over 12 years of employment at Covance he has risen to the position of European Lead for Immunology and Immunotoxicology with responsibilities for teams based in Harrogate, Huntingdon and Muenster.

Message Presenter
Chris Cooper, Covance by Labcorp

Chris Cooper, Subject Matter Expert, Manager, Covance by Labcorp

Christopher Cooper has worked in the pharmaceutical industry within Covance Clinical Pathology and the Immunology & Immunotoxicology (I&I) departments for the past 14 years. Over his early career Christopher has developed expertise in a diverse range of critical Immunology techniques including flow cytometry, Immunoassays & complex tissue culture previously as a subject matter expert. Over time, Christopher has played an integral role is developing & specializing in cell bases assay capabilities with a primary focus human/preclinical in vitro alternatives, ex vivo functional cell based assays including ELISpot & Flourospot.

Christopher has also over the past ~9 years gained expertise in supporting pre-clinical & clinical gene therapy programmes. His current role within the organization is now as a subject matter expert (SME) manager within the Immunology & Immunotoxicology group.

Message Presenter

Who Should Attend?

This webinar will appeal to individuals with the following or related job titles:

  • Research and Development Director
  • Operational Director
  • Bioanalytical scientist
  • Study Director
  • Immunologist

What You Will Learn

 In this webinar, participants will learn:

  • When to consider Immunology and Immunotoxicology assessments
  • How to assess the immune response
  • The range of immunology endpoint assessments available and their respective uses for developing safe and effective therapeutics

Xtalks Partner

Covance by Labcorp

Covance by Labcorp is a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 26,000 people worldwide, we provide comprehensive drug development solutions and are on a mission to advance health and power clear, confident decisions.

Covance by Labcorp is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise.

Together with our clients, Covance by Labcorp supports the development of innovative, life-changing treatments. Visit us at

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account